

David M Margolis

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/341668/david-m-margolis-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

206
papers

15,847
citations

66
h-index

121
g-index

233
ext. papers

18,831
ext. citations

9.4
avg, IF

6.47
L-index

#	Paper	IF	Citations
206	Latency Reversal and Clearance of Persistent HIV Infection.. <i>Methods in Molecular Biology</i> , 2022 , 2407, 375-389	1.4	
205	Crotonylation sensitizes IAPi-induced disruption of latent HIV by enhancing p100 cleavage into p52.. <i>IScience</i> , 2022 , 25, 103649	6.1	2
204	Discovery of a large-scale, cell-state-responsive allosteric switch in the 7SK RNA using DANCE-MaP.. <i>Molecular Cell</i> , 2022 ,	17.6	3
203	Altered Response Pattern following AZD5582 Treatment of SIV-Infected, ART-Suppressed Rhesus Macaque Infants.. <i>Journal of Virology</i> , 2022 , e0169921	6.6	0
202	Longitudinal Dynamics of Intact HIV Proviral DNA and Outgrowth Virus Frequencies in a Cohort of Individuals Receiving Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2021 , 224, 92-100	7	9
201	Multi-omics analyses reveal that HIV-1 alters CD4 T cell immunometabolism to fuel virus replication. <i>Nature Immunology</i> , 2021 , 22, 423-433	19.1	16
200	Frequency of post treatment control varies by antiretroviral therapy restart and viral load criteria. <i>Aids</i> , 2021 , 35, 2225-2227	3.5	3
199	Immunological Correlates of the HIV-1 Replication-Competent Reservoir Size. <i>Clinical Infectious Diseases</i> , 2021 , 73, 1528-1531	11.6	1
198	Measuring the Haystack@ Needles. <i>Journal of Infectious Diseases</i> , 2021 , 223, 184-186	7	0
197	Epigenomic characterization of latent HIV infection identifies latency regulating transcription factors. <i>PLoS Pathogens</i> , 2021 , 17, e1009346	7.6	6
196	Sequence Evaluation and Comparative Analysis of Novel Assays for Intact Proviral HIV-1 DNA. <i>Journal of Virology</i> , 2021 , 95,	6.6	11
195	Sex disparities and neutralizing antibody durability to SARS-CoV-2 infection in convalescent individuals 2021 ,		8
194	CD8 lymphocyte depletion enhances the latency reversal activity of the SMAC mimetic AZD5582 in ART-suppressed SIV-infected rhesus macaques. <i>Journal of Virology</i> , 2021 ,	6.6	8
193	Sex Disparities and Neutralizing-Antibody Durability to SARS-CoV-2 Infection in Convalescent Individuals. <i>MSphere</i> , 2021 , 6, e0027521	5	11
192	Elimination of SHIV Infected Cells by Combinations of Bispecific HIVxCD3 DART Molecules. <i>Frontiers in Immunology</i> , 2021 , 12, 710273	8.4	0
191	Evaluation of EED Inhibitors as a Class of PRC2-Targeted Small Molecules for HIV Latency Reversal. <i>ACS Infectious Diseases</i> , 2020 , 6, 1719-1733	5.5	6
190	SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract. <i>Cell</i> , 2020 , 182, 429-446.e14	56.2	710

189	Impact of Biological Sex on Immune Activation and Frequency of the Latent HIV Reservoir During Suppressive Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2020 , 222, 1843-1852	7	9
188	The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. <i>Science Immunology</i> , 2020 , 5,	28	450
187	CTLA-4 and PD-1 dual blockade induces SIV reactivation without control of rebound after antiretroviral therapy interruption. <i>Nature Medicine</i> , 2020 , 26, 519-528	50.5	30
186	Assessing the impact of AGS-004, a dendritic cell-based immunotherapy, and vorinostat on persistent HIV-1 Infection. <i>Scientific Reports</i> , 2020 , 10, 5134	4.9	13
185	Curing HIV: Seeking to Target and Clear Persistent Infection. <i>Cell</i> , 2020 , 181, 189-206	56.2	48
184	Robust and persistent reactivation of SIV and HIV by N-803 and depletion of CD8 cells. <i>Nature</i> , 2020 , 578, 154-159	50.4	70
183	Systemic HIV and SIV latency reversal via non-canonical NF- κ B signalling in vivo. <i>Nature</i> , 2020 , 578, 160-165	50.4	102
182	Improved killing of HIV-infected cells using three neutralizing and non-neutralizing antibodies. <i>Journal of Clinical Investigation</i> , 2020 , 130, 5157-5170	15.9	12
181	The HIV-1 latent reservoir is largely sensitive to circulating T cells. <i>ELife</i> , 2020 , 9,	8.9	9
180	Degradation of Polycomb Repressive Complex 2 with an EED-Targeted Bivalent Chemical Degradator. <i>Cell Chemical Biology</i> , 2020 , 27, 47-56.e15	8.2	74
179	Highlights of the 9th edition of the Conference on HIV Persistence During Therapy, 10-13 December 2019, Miami, USA. <i>Journal of Virus Eradication</i> , 2020 , 6, 85-95	2.8	
178	Efficacy, pharmacokinetics and neurocognitive performance of dual, NRTI-sparing antiretroviral therapy in acute HIV-infection. <i>Aids</i> , 2020 , 34, 1923-1931	3.5	3
177	SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo. <i>Science</i> , 2020 , 370, 1464-1468	33.3	517
176	Measuring the Inducible, Replication-Competent HIV Reservoir Using an Ultra-Sensitive p24 Readout, the Digital ELISA Viral Outgrowth Assay. <i>Frontiers in Immunology</i> , 2020 , 11, 1971	8.4	8
175	SMAC Mimetic Plus Triple-Combination Bispecific HIVxCD3 Retargeting Molecules in SHIV.C.CH505-Infected, Antiretroviral Therapy-Suppressed Rhesus Macaques. <i>Journal of Virology</i> , 2020 , 94,	6.6	17
174	Cellular Gene Modulation of HIV-Infected CD4 T Cells in Response to Serial Treatment with the Histone Deacetylase Inhibitor Vorinostat. <i>Journal of Virology</i> , 2020 , 94,	6.6	2
173	HIV-Specific T Cell Responses Are Highly Stable on Antiretroviral Therapy. <i>Molecular Therapy - Methods and Clinical Development</i> , 2019 , 15, 9-17	6.4	11
172	How Unavoidable Are Analytical Treatment Interruptions in HIV Cure-Related Studies?. <i>Journal of Infectious Diseases</i> , 2019 , 220, S24-S26	7	9

171	The replication-competent HIV-1 latent reservoir is primarily established near the time of therapy initiation. <i>Science Translational Medicine</i> , 2019 , 11,	17.5	66
170	Four Weeks of Treatment With Rifaximin Fails to Significantly Alter Microbial Diversity in Rectal Samples of HIV-Infected Immune Non-Responders (ACTG A5286) Which May be Attributed to Rectal Swab Use. <i>Pathogens and Immunity</i> , 2019 , 4, 235-250	4.9	2
169	New Frontiers in Measuring and Characterizing the HIV Reservoir. <i>Frontiers in Microbiology</i> , 2019 , 10, 2878	5.7	28
168	In-vivo administration of histone deacetylase inhibitors does not impair natural killer cell function in HIV+ individuals. <i>Aids</i> , 2019 , 33, 605-613	3.5	13
167	HIV-Specific T Cells Generated from Naive T Cells Suppress HIV In Vitro and Recognize Wide Epitope Breadths. <i>Molecular Therapy</i> , 2018 , 26, 1435-1446	11.7	12
166	Countering HIV - Three@ the Charm?. <i>New England Journal of Medicine</i> , 2018 , 378, 295-297	59.2	3
165	Interleukin-15-Stimulated Natural Killer Cells Clear HIV-1-Infected Cells following Latency Reversal. <i>Journal of Virology</i> , 2018 , 92,	6.6	56
164	Immunogenicity of AGS-004 Dendritic Cell Therapy in Patients Treated During Acute HIV Infection. <i>AIDS Research and Human Retroviruses</i> , 2018 , 34, 111-122	1.6	32
163	HIV Persistence on Antiretroviral Therapy and Barriers to a Cure. <i>Advances in Experimental Medicine and Biology</i> , 2018 , 1075, 165-185	3.6	17
162	The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies. <i>Journal of Infectious Diseases</i> , 2018 , 218, 1954-1963	7	77
161	T cells: an immunotherapeutic approach for HIV cure strategies. <i>JCI Insight</i> , 2018 , 3,	9.9	14
160	HIV-1 proviral landscapes distinguish posttreatment controllers from noncontrollers. <i>Journal of Clinical Investigation</i> , 2018 , 128, 4074-4085	15.9	40
159	HIV latency is reversed by ACSS2-driven histone crotonylation. <i>Journal of Clinical Investigation</i> , 2018 , 128, 1190-1198	15.9	59
158	Highlights from the 8th International Workshop on HIV Persistence during Therapy, 12-15 December 2017, Miami, FL, USA. <i>Journal of Virus Eradication</i> , 2018 , 4, 132-142	2.8	
157	Determinants of the efficacy of HIV latency-reversing agents and implications for drug and treatment design. <i>JCI Insight</i> , 2018 , 3,	9.9	8
156	HIV-Specific, Ex Vivo Expanded T Cell Therapy: Feasibility, Safety, and Efficacy in ART-Suppressed HIV-Infected Individuals. <i>Molecular Therapy</i> , 2018 , 26, 2496-2506	11.7	18
155	Single-Cell Analysis of Quiescent HIV Infection Reveals Host Transcriptional Profiles that Regulate Proviral Latency. <i>Cell Reports</i> , 2018 , 25, 107-117.e3	10.6	45
154	HIV antibodies for treatment of HIV infection. <i>Immunological Reviews</i> , 2017 , 275, 313-323	11.3	46

153	Benzotriazoles Reactivate Latent HIV-1 through Inactivation of STAT5 SUMOylation. <i>Cell Reports</i> , 2017 , 18, 1324-1334	10.6	47
152	Radiation-free, alternative-donor HCT for Fanconi anemia patients: results from a prospective multi-institutional study. <i>Blood</i> , 2017 , 129, 2308-2315	2.2	47
151	Proviral Latency, Persistent Human Immunodeficiency Virus Infection, and the Development of Latency Reversing Agents. <i>Journal of Infectious Diseases</i> , 2017 , 215, S111-S118	7	41
150	Detection of human immunodeficiency virus RNAs in living cells using Spinach RNA aptamers. <i>Virus Research</i> , 2017 , 228, 141-146	6.4	6
149	Vorinostat Renders the Replication-Competent Latent Reservoir of Human Immunodeficiency Virus (HIV) Vulnerable to Clearance by CD8 T Cells. <i>EBioMedicine</i> , 2017 , 23, 52-58	8.8	25
148	Quantification of the Latent HIV-1 Reservoir Using Ultra Deep Sequencing and Primer ID in a Viral Outgrowth Assay. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017 , 74, 221-228	3.1	17
147	Interrupting antiretroviral treatment in HIV cure research: scientific and ethical considerations. <i>Journal of Virus Eradication</i> , 2017 , 3, 82-84	2.8	36
146	HDAC inhibition induces HIV-1 protein and enables immune-based clearance following latency reversal. <i>JCI Insight</i> , 2017 , 2,	9.9	45
145	Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latency. <i>Journal of Clinical Investigation</i> , 2017 , 127, 3126-3135	15.9	111
144	Chromatin Regulation and the Histone Code in HIV Latency?. <i>Yale Journal of Biology and Medicine</i> , 2017 , 90, 229-243	2.4	25
143	Highlights from the Seventh International Workshop on HIV Persistence during Therapy, 8-11 December 2015, Miami, Florida, USA. <i>Journal of Virus Eradication</i> , 2016 , 2, 57-65	2.8	6
142	Ten Years of Screening and Testing for Acute HIV Infection in North Carolina. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016 , 71, 111-9	3.1	20
141	In vivo analysis of the effect of panobinostat on cell-associated HIV RNA and DNA levels and latent HIV infection. <i>Retrovirology</i> , 2016 , 13, 36	3.6	41
140	Latency reversal and viral clearance to cure HIV-1. <i>Science</i> , 2016 , 353, aaf6517	33.3	159
139	A trial of unrelated donor marrow transplantation for children with severe sickle cell disease. <i>Blood</i> , 2016 , 128, 2561-2567	2.2	123
138	Fixed-dose combination emtricitabine/tenofovir/efavirenz initiated during acute HIV infection; 96-week efficacy and durability. <i>Aids</i> , 2016 , 30, 2815-2822	3.5	4
137	HIV reservoirs: what, where and how to target them. <i>Nature Reviews Microbiology</i> , 2016 , 14, 55-60	22.2	176
136	Transcriptomic Analysis Implicates the p53 Signaling Pathway in the Establishment of HIV-1 Latency in Central Memory CD4 T Cells in an In Vitro Model. <i>PLoS Pathogens</i> , 2016 , 12, e1006026	7.6	20

135	Highlights from the Seventh International Workshop on HIV Persistence during Therapy, 8-11 December 2015, Miami, Florida, USA. <i>Journal of Virus Eradication</i> , 2016 , 2, 57-65	2.8	3
134	HIV Latency-Reversing Agents Have Diverse Effects on Natural Killer Cell Function. <i>Frontiers in Immunology</i> , 2016 , 7, 356	8.4	38
133	Dendritic Cell Immunotherapy for HIV-1 Infection Using Autologous HIV-1 RNA: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016 , 72, 31-8	3.1	58
132	International AIDS Society global scientific strategy: towards an HIV cure 2016. <i>Nature Medicine</i> , 2016 , 22, 839-50	50.5	303
131	The differential short- and long-term effects of HIV-1 latency-reversing agents on T cell function. <i>Scientific Reports</i> , 2016 , 6, 30749	4.9	47
130	Envelope-specific antibodies and antibody-derived molecules for treating and curing HIV infection. <i>Nature Reviews Drug Discovery</i> , 2016 , 15, 823-834	64.1	41
129	Expanded cytotoxic T-cell lymphocytes target the latent HIV reservoir. <i>Journal of Infectious Diseases</i> , 2015 , 212, 258-63	7	71
128	Broadly-specific cytotoxic T cells targeting multiple HIV antigens are expanded from HIV+ patients: implications for immunotherapy. <i>Molecular Therapy</i> , 2015 , 23, 387-95	11.7	36
127	Rifaximin has a marginal impact on microbial translocation, T-cell activation and inflammation in HIV-positive immune non-responders to antiretroviral therapy - ACTG A5286. <i>Journal of Infectious Diseases</i> , 2015 , 211, 780-90	7	52
126	Gold nanoparticles to improve HIV drug delivery. <i>Future Medicinal Chemistry</i> , 2015 , 7, 1097-107	4.1	47
125	Mixed effects of suberoylanilide hydroxamic acid (SAHA) on the host transcriptome and proteome and their implications for HIV reactivation from latency. <i>Antiviral Research</i> , 2015 , 123, 78-85	10.8	23
124	Translational challenges in targeting latent HIV infection and the CNS reservoir problem. <i>Journal of NeuroVirology</i> , 2015 , 21, 222-6	3.9	7
123	Characterizing the Switching Thresholds of Magnetophoretic Transistors. <i>Advanced Materials</i> , 2015 , 27, 6176-80	24	22
122	Dose-responsive gene expression in suberoylanilide hydroxamic acid-treated resting CD4+ T cells. <i>Aids</i> , 2015 , 29, 2235-44	3.5	16
121	Peripheral VβVβ T Cells Are a Novel Reservoir of Latent HIV Infection. <i>PLoS Pathogens</i> , 2015 , 11, e1005206	20.6	50
120	Dual-Affinity Re-Targeting proteins direct T cell-mediated cytolysis of latently HIV-infected cells. <i>Journal of Clinical Investigation</i> , 2015 , 125, 4077-90	15.9	104
119	H3K27 Demethylation at the Proviral Promoter Sensitizes Latent HIV to the Effects of Vorinostat in Ex Vivo Cultures of Resting CD4+ T Cells. <i>Journal of Virology</i> , 2015 , 89, 8392-405	6.6	43
118	Precise Quantitation of the Latent HIV-1 Reservoir: Implications for Eradication Strategies. <i>Journal of Infectious Diseases</i> , 2015 , 212, 1361-5	7	252

117	How Might We Cure HIV?. <i>Current Infectious Disease Reports</i> , 2014 , 16, 392	3.9	22
116	Eradicating HIV-1 infection: seeking to clear a persistent pathogen. <i>Nature Reviews Microbiology</i> , 2014 , 12, 750-64	22.2	202
115	Framing expectations in early HIV cure research. <i>Trends in Microbiology</i> , 2014 , 22, 547-9	12.4	45
114	Quantitation of replication-competent HIV-1 in populations of resting CD4+ T cells. <i>Journal of Virology</i> , 2014 , 88, 14070-7	6.6	110
113	Therapy for latent HIV-1 infection: the role of histone deacetylase inhibitors. <i>Antiviral Chemistry and Chemotherapy</i> , 2014 , 23, 145-9	3.5	41
112	Targeted cytotoxic therapy kills persisting HIV infected cells during ART. <i>PLoS Pathogens</i> , 2014 , 10, e1003872	8.5	85
111	HIV-1 expression within resting CD4+ T cells after multiple doses of vorinostat. <i>Journal of Infectious Diseases</i> , 2014 , 210, 728-35	7	191
110	Words matter: Discussing research towards an HIV cure in research and clinical contexts. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014 , 67, e110-1	3.1	33
109	Emerging strategies to deplete the HIV reservoir. <i>Current Opinion in Infectious Diseases</i> , 2014 , 27, 29-35	5.4	130
108	HIV/AIDS. Persistence by proliferation?. <i>Science</i> , 2014 , 345, 143-4	33.3	12
107	HLA-B*57 elite suppressor and chronic progressor HIV-1 isolates replicate vigorously and cause CD4+ T cell depletion in humanized BLT mice. <i>Journal of Virology</i> , 2014 , 88, 3340-52	6.6	36
106	Selective HDAC inhibition for the disruption of latent HIV-1 infection. <i>PLoS ONE</i> , 2014 , 9, e102684	3.7	51
105	Prospects for treatment of latent HIV. <i>Clinical Pharmacology and Therapeutics</i> , 2013 , 93, 46-56	6.1	68
104	Change-point models to estimate the limit of detection. <i>Statistics in Medicine</i> , 2013 , 32, 4995-5007	2.3	4
103	Acute HIV-1 infection in the Southeastern United States: a cohort study. <i>AIDS Research and Human Retroviruses</i> , 2013 , 29, 121-8	1.6	31
102	Snapshots: chromatin control of viral infection. <i>Virology</i> , 2013 , 435, 141-56	3.6	116
101	An in-depth comparison of latent HIV-1 reactivation in multiple cell model systems and resting CD4+ T cells from aviremic patients. <i>PLoS Pathogens</i> , 2013 , 9, e1003834	7.6	283
100	Combined approaches for HIV cure. <i>Current Opinion in HIV and AIDS</i> , 2013 , 8, 230-5	4.2	51

99	Selective targeting of the repressive transcription factors YY1 and cMyc to disrupt quiescent human immunodeficiency viruses. <i>AIDS Research and Human Retroviruses</i> , 2013 , 29, 289-98	1.6	9
98	HIV-1 infection, response to treatment and establishment of viral latency in a novel humanized T cell-only mouse (TOM) model. <i>Retrovirology</i> , 2013 , 10, 121	3.6	52
97	Antiretroviral therapy initiated during acute HIV infection fails to prevent persistent T-cell activation. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013 , 62, 505-8	3.1	44
96	Reactivation of latent HIV-1 in central memory CD4+ T cells through TLR-1/2 stimulation. <i>Retrovirology</i> , 2013 , 10, 119	3.6	88
95	Predictors of residual viraemia in patients on long-term suppressive antiretroviral therapy. <i>Antiviral Therapy</i> , 2013 , 18, 39-43	1.6	18
94	Towards an HIV cure: a global scientific strategy. <i>Nature Reviews Immunology</i> , 2012 , 12, 607-14	36.5	414
93	BET bromodomain inhibition as a novel strategy for reactivation of HIV-1. <i>Journal of Leukocyte Biology</i> , 2012 , 92, 1147-54	6.5	194
92	Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. <i>Nature</i> , 2012 , 487, 482-5	50.4	844
91	Immediate antiviral therapy appears to restrict resting CD4+ cell HIV-1 infection without accelerating the decay of latent infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, 9523-8	11.5	170
90	Amelioration of oral mucositis pain by NASA near-infrared light-emitting diodes in bone marrow transplant patients. <i>Supportive Care in Cancer</i> , 2012 , 20, 1405-15	3.9	46
89	IL-2 receptor β chain molecule is critical for intestinal T-cell reconstitution in humanized mice. <i>Mucosal Immunology</i> , 2012 , 5, 555-66	9.2	65
88	Generation of HIV latency in humanized BLT mice. <i>Journal of Virology</i> , 2012 , 86, 630-4	6.6	155
87	Latent HIV-1 infection of resting CD4+ T cells in the humanized Rag2 ^{+/+} μ 29 ^{+/+} mouse. <i>Journal of Virology</i> , 2012 , 86, 114-20	6.6	67
86	Association of HIV neutralizing antibody with lower viral load after treatment interruption in a prospective trial (A5170). <i>Aids</i> , 2012 , 26, 1452	3.5	7
85	Association of HIV neutralizing antibody with lower viral load after treatment interruption in a prospective trial (A5170). <i>Aids</i> , 2012 , 26, 1-9	3.5	7
84	No effect of raltegravir intensification on viral replication markers in the blood of HIV-1-infected patients receiving antiretroviral therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012 , 59, 229-35	3.1	87
83	Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated. <i>Journal of Experimental Medicine</i> , 2011 , 208, 2237-49	16.6	166
82	Curing HIV: Pharmacologic approaches to target HIV-1 latency. <i>Annual Review of Pharmacology and Toxicology</i> , 2011 , 51, 397-418	17.9	61

81	Cross-sectional detection of acute HIV infection: timing of transmission, inflammation and antiretroviral therapy. <i>PLoS ONE</i> , 2011 , 6, e19617	3.7	58
80	Efficacy of NNRTI-based antiretroviral therapy initiated during acute HIV infection. <i>Aids</i> , 2011 , 25, 941-9	3.5	22
79	Histone deacetylase inhibitors and HIV latency. <i>Current Opinion in HIV and AIDS</i> , 2011 , 6, 25-9	4.2	96
78	Epigenetic silencing of HIV-1 by the histone H3 lysine 27 methyltransferase enhancer of Zeste 2. <i>Journal of Virology</i> , 2011 , 85, 9078-89	6.6	193
77	Disulfiram reactivates latent HIV-1 in a Bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation. <i>Journal of Virology</i> , 2011 , 85, 6060-4	6.6	155
76	Clonal sequences recovered from plasma from patients with residual HIV-1 viremia and on intensified antiretroviral therapy are identical to replicating viral RNAs recovered from circulating resting CD4+ T cells. <i>Journal of Virology</i> , 2011 , 85, 5220-3	6.6	72
75	Eradication therapies for HIV Infection: time to begin again. <i>AIDS Research and Human Retroviruses</i> , 2011 , 27, 347-53	1.6	31
74	Spatiotemporal trafficking of HIV in human plasmacytoid dendritic cells defines a persistently IFN- β -producing and partially matured phenotype. <i>Journal of Clinical Investigation</i> , 2011 , 121, 1088-101	15.9	102
73	The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. <i>PLoS Medicine</i> , 2010 , 7, e1000321	11.6	222
72	Neurocognitive effects of treatment interruption in stable HIV-positive patients in an observational cohort. <i>Neurology</i> , 2010 , 74, 1260-6	6.5	166
71	Therapy for persistent HIV. <i>Trends in Pharmacological Sciences</i> , 2010 , 31, 206-11	13.2	11
70	Evidence of dysregulation of dendritic cells in primary HIV infection. <i>Blood</i> , 2010 , 116, 3839-52	2.2	137
69	Mechanisms of HIV latency: an emerging picture of complexity. <i>Current HIV/AIDS Reports</i> , 2010 , 7, 37-43	5.9	70
68	Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection. <i>PLoS ONE</i> , 2010 , 5, e9390	3.7	123
67	A limited group of class I histone deacetylases acts to repress human immunodeficiency virus type 1 expression. <i>Journal of Virology</i> , 2009 , 83, 4749-56	6.6	156
66	Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy: final 48-week clinical and virologic outcomes. <i>Journal of Infectious Diseases</i> , 2009 , 199, 866-71	7	43
65	Polyclonal B cell differentiation and loss of gastrointestinal tract germinal centers in the earliest stages of HIV-1 infection. <i>PLoS Medicine</i> , 2009 , 6, e1000107	11.6	129
64	Suppression of human immunodeficiency virus type 1 (HIV-1) viremia with reverse transcriptase and integrase inhibitors, CD4+ T-cell recovery, and viral rebound upon interruption of therapy in a new model for HIV treatment in the humanized Rag2-/- γ c-/- mouse. <i>Journal of Virology</i> , 2009 , 83, 8254-8	6.6	68

63	Pharmaceutical approaches to eradication of persistent HIV infection. <i>Expert Reviews in Molecular Medicine</i> , 2009 , 11, e6	6.7	27
62	Expression of latent human immunodeficiency type 1 is induced by novel and selective histone deacetylase inhibitors. <i>Aids</i> , 2009 , 23, 1799-806	3.5	137
61	Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. <i>AIDS Research and Human Retroviruses</i> , 2009 , 25, 207-12	1.6	282
60	The challenge of finding a cure for HIV infection. <i>Science</i> , 2009 , 323, 1304-7	33.3	682
59	Prevalence of pressure ulcers on hospital admission among nursing home residents transferred to the hospital. <i>Wound Repair and Regeneration</i> , 2008 , 16, 331-6	3.6	51
58	Inhibition of HIV fusion with multivalent gold nanoparticles. <i>Journal of the American Chemical Society</i> , 2008 , 130, 6896-7	16.4	294
57	Improved measures of quality of life, lipid profile, and lipoatrophy after treatment interruption in HIV-infected patients with immune preservation: results of ACTG 5170. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2008 , 49, 377-83	3.1	7
56	Detection of nonnucleoside reverse-transcriptase inhibitor-resistant HIV-1 after discontinuation of virologically suppressive antiretroviral therapy. <i>Clinical Infectious Diseases</i> , 2008 , 47, 421-4	11.6	28
55	Hexamethylbisacetamide and disruption of human immunodeficiency virus type 1 latency in CD4(+) T cells. <i>Journal of Infectious Diseases</i> , 2008 , 197, 1162-70	7	66
54	Reply to Cooper et al. <i>Journal of Infectious Diseases</i> , 2008 , 197, 775-776	7	1
53	CD4+ T-cell decline after the interruption of antiretroviral therapy in ACTG A5170 is predicted by differential expression of genes in the ras signaling pathway. <i>AIDS Research and Human Retroviruses</i> , 2008 , 24, 1047-66	1.6	7
52	Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells. <i>Aids</i> , 2008 , 22, 1131-5	3.5	143
51	Confronting proviral HIV infection. <i>Current HIV/AIDS Reports</i> , 2007 , 4, 60-4	5.9	11
50	c-Myc and Sp1 contribute to proviral latency by recruiting histone deacetylase 1 to the human immunodeficiency virus type 1 promoter. <i>Journal of Virology</i> , 2007 , 81, 10914-23	6.6	183
49	Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170. <i>Journal of Infectious Diseases</i> , 2007 , 195, 1426-36	7	55
48	Eliminating persistent HIV infection: getting to the end of the rainbow. <i>Journal of Infectious Diseases</i> , 2007 , 195, 1734-6	7	5
47	Treatment for lipoatrophy: facing the real costs. <i>Aids</i> , 2007 , 21, 1819-20	3.5	3
46	The use of beta-D-2,6-diaminopurine dioxolane with or without mycophenolate mofetil in drug-resistant HIV infection. <i>Aids</i> , 2007 , 21, 2025-32	3.5	19

45	Abacavir and Mycophenolic Acid, an Inhibitor of Inosine Monophosphate Dehydrogenase, Have Profound and Synergistic Anti-HIV Activity. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 2006 , 21, 362		10
44	Attacking HIV provirus: therapeutic strategies to disrupt persistent infection. <i>Infectious Disorders - Drug Targets</i> , 2006 , 6, 369-76	1.1	10
43	Cyclosporin A provides no sustained immunologic benefit to persons with chronic HIV-1 infection starting suppressive antiretroviral therapy: results of a randomized, controlled trial of the AIDS Clinical Trials Group A5138. <i>Journal of Infectious Diseases</i> , 2006 , 194, 1677-85	7	34
42	Hexamethylbisacetamide remodels the human immunodeficiency virus type 1 (HIV-1) promoter and induces Tat-independent HIV-1 expression but blunts cell activation. <i>Journal of Virology</i> , 2006 , 80, 4570-9	6.6	38
41	Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression. <i>JAMA - Journal of the American Medical Association</i> , 2006 , 296, 806-14	27.4	68
40	A placebo-controlled pilot study of intensification of antiretroviral therapy with mycophenolate mofetil. <i>AIDS Research and Therapy</i> , 2006 , 3, 16	3	5
39	A prospective evaluation of the effect of atazanavir on the QTc interval and QTc dispersion in HIV-positive patients. <i>HIV Medicine</i> , 2006 , 7, 317-22	2.7	43
38	Lipid abnormalities in HIV/hepatitis C virus-coinfected patients. <i>HIV Medicine</i> , 2006 , 7, 530-6	2.7	25
37	Attacking latent HIV provirus: from mechanism to therapeutic strategies. <i>Current Opinion in HIV and AIDS</i> , 2006 , 1, 134-40	4.2	5
36	Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. <i>Lancet, The</i> , 2005 , 366, 549-55	40	454
35	Mitogen-activated protein kinases regulate LSF occupancy at the human immunodeficiency virus type 1 promoter. <i>Journal of Virology</i> , 2005 , 79, 5952-62	6.6	18
34	Ex vivo modeling of the effects of mycophenolic acid on HIV infection: considerations for antiviral therapy. <i>AIDS Research and Human Retroviruses</i> , 2005 , 21, 116-24	1.6	14
33	Polyamides reveal a role for repression in latency within resting T cells of HIV-infected donors. <i>Journal of Infectious Diseases</i> , 2004 , 190, 1429-37	7	52
32	Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression. <i>Aids</i> , 2004 , 18, 1101-8	3.5	208
31	Interleukin-7 induces HIV type 1 outgrowth from peripheral resting CD4+ T cells. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2004 , 36, 1103-4	3.1	30
30	Atazanavir for the treatment of human immunodeficiency virus infection. <i>Pharmacotherapy</i> , 2004 , 24, 1732-47	5.8	78
29	Glucose production pathways by 2H and 13C NMR in patients with HIV-associated lipodystrophy. <i>Magnetic Resonance in Medicine</i> , 2004 , 51, 649-54	4.4	23
28	Compact quadruple therapy with the lamivudine/zidovudine combination tablet plus abacavir and efavirenz, followed by the lamivudine/zidovudine/abacavir triple nucleoside tablet plus efavirenz in treatment-naïve HIV-infected adults. <i>HIV Clinical Trials</i> , 2003 , 4, 231-43		6

27	Safety and immunogenicity of a heptavalent pneumococcal conjugate vaccine in infants with human immunodeficiency virus type 1 infection. <i>Pediatrics</i> , 2003 , 112, 66-73	7.4	76
26	Noninvasive evaluation of liver metabolism by ² H and ¹³ C NMR isotopomer analysis of human urine. <i>Analytical Biochemistry</i> , 2003 , 312, 228-34	3.1	51
25	Targeted derepression of the human immunodeficiency virus type 1 long terminal repeat by pyrrole-imidazole polyamides. <i>Journal of Virology</i> , 2002 , 76, 12349-54	6.6	64
24	The regulation of HIV-1 gene expression: the emerging role of chromatin. <i>DNA and Cell Biology</i> , 2002 , 21, 697-705	3.6	44
23	Counterregulation of chromatin deacetylation and histone deacetylase occupancy at the integrated promoter of human immunodeficiency virus type 1 (HIV-1) by the HIV-1 repressor YY1 and HIV-1 activator Tat. <i>Molecular and Cellular Biology</i> , 2002 , 22, 2965-73	4.8	201
22	The addition of mycophenolate mofetil to antiretroviral therapy including abacavir is associated with depletion of intracellular deoxyguanosine triphosphate and a decrease in plasma HIV-1 RNA. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2002 , 31, 45-9	3.1	65
21	Dose proportional inhibition of HIV-1 replication by mycophenolic acid and synergistic inhibition in combination with abacavir, didanosine, and tenofovir. <i>Antiviral Research</i> , 2002 , 55, 41-52	10.8	62
20	A Pilot Study of the Use of Mycophenolate Mofetil as a Component of Therapy for Multidrug-Resistant HIV-1 Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2001 , 26, 423-434	3.1	19
19	Inhibition of HIV Replication by A77 1726, the Active Metabolite of Leflunomide, in Combination With Pyrimidine Nucleoside Reverse Transcriptase Inhibitors. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2001 , 28, 199-201	3.1	7
18	A pilot study of the use of mycophenolate mofetil as a component of therapy for multidrug-resistant HIV-1 infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2001 , 26, 423-34	3.1	52
17	Higher macrophage inflammatory protein (MIP)-1alpha and MIP-1beta levels from CD8+ T cells are associated with asymptomatic HIV-1 infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000 , 97, 13812-7	11.5	103
16	The human factors YY1 and LSF repress the human immunodeficiency virus type 1 long terminal repeat via recruitment of histone deacetylase 1. <i>Journal of Virology</i> , 2000 , 74, 6790-9	6.6	291
15	Abacavir in combination with the inosine monophosphate dehydrogenase (IMPDH)-inhibitor mycophenolic acid is active against multidrug-resistant HIV-1. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 1999 , 22, 406-7	3.1	19
14	Abacavir and Mycophenolic Acid, an Inhibitor of Inosine Monophosphate Dehydrogenase, Have Profound and Synergistic Anti-HIV Activity. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 1999 , 21, 362	3.1	84
13	Abacavir and Mycophenolic Acid, an Inhibitor of Inosine Monophosphate Dehydrogenase, Have Profound and Synergistic Anti-HIV Activity. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1999 , 21, 362		37
12	Abacavir in Combination With the Inosine Monophosphate Dehydrogenase (IMPDH) Inhibitor Mycophenolic Acid Is Active Against Multidrug-Resistant HIV-1. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 1999 , 22, 406	3.1	27
11	Activation of CD8+ T lymphocytes through the T cell receptor turns on CD4 gene expression: implications for HIV pathogenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1998 , 95, 3111-6	11.5	123
10	Induction and enhancement of immune responses to herpes simplex virus type 2 in humans by use of a recombinant glycoprotein D vaccine. <i>Journal of Infectious Diseases</i> , 1993 , 167, 1045-52	7	54

9	A cutaneous lesion in a patient with AIDS: an unusual presentation of infection due to <i>Mycobacterium avium</i> complex. <i>Clinical Infectious Diseases</i> , 1993 , 16, 555-7	11.6	14
8	HSV-1 activation of HIV-1 transcription is augmented by a cellular protein that binds near the initiator element. <i>Virology</i> , 1993 , 192, 370-4	3.6	28
7	Transactivation of the HIV-1 LTR by HSV-1 immediate-early genes. <i>Virology</i> , 1992 , 186, 788-91	3.6	81
6	Trimethoprim-sulfamethoxazole prophylaxis in the management of chronic granulomatous disease. <i>Journal of Infectious Diseases</i> , 1990 , 162, 723-6	7	219
5	Digital necrosis and disseminated <i>Pneumocystis carinii</i> infection after aerosolized pentamidine prophylaxis. <i>Annals of Internal Medicine</i> , 1989 , 111, 681-2	8	53
4	Effect of the weaver (wv) mutation on cerebellar neuron differentiation. I. Qualitative observations of neuron behavior in culture. <i>Developmental Biology</i> , 1985 , 107, 156-72	3.1	33
3	Effect of the weaver (wv) mutation on cerebellar neuron differentiation. II. Quantitation of neuron behavior in culture. <i>Developmental Biology</i> , 1985 , 107, 173-9	3.1	21
2	Neuronal differentiation in cultures of weaver (wv) mutant mouse cerebellum. <i>Journal of Supramolecular Structure and Cellular Biochemistry</i> , 1981 , 17, 79-86		16
1	The SMAC Mimetic AZD5582 is a Potent HIV Latency Reversing Agent		7